Study of Chemo-Immunotherapy in Head and Neck Cancer Patients
The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients with relapsed and refractory head and neck squamous cell carcinoma.
Head and Neck Cancer
BIOLOGICAL: Cyclophosphamide, Docetaxel, Dendritic cells, OK-432
The safety and feasibility of chemo-immunotherapy, 1 year
The number and function of immune effector cells in treated patients, 1 year
The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients with relapsed and refractory head and neck squamous cell carcinoma.